There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Gilead Sciences (GILD – Research Report), Tivity Health (TVTY – Research Report) and AbbVie (ABBV – Research Report) with bullish sentiments.
Gilead Sciences (GILD)
In a report released today, Evan Seigerman from BMO Capital maintained a Buy rating on Gilead Sciences, with a price target of $85.00. The company’s shares closed last Tuesday at $70.52.
According to TipRanks.com, Seigerman is a 4-star analyst with an average return of 11.8% and a 50.6% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Mirati Therapeutics, and Merck & Company.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Gilead Sciences with a $77.62 average price target, an 11.1% upside from current levels. In a report issued on December 8, Jefferies also maintained a Buy rating on the stock with a $80.00 price target.
See the top stocks recommended by analysts >>
Tivity Health (TVTY)
Barrington analyst Michael Petusky maintained a Buy rating on Tivity Health today and set a price target of $33.00. The company’s shares closed last Tuesday at $24.30.
According to TipRanks.com, Petusky is a 4-star analyst with an average return of 9.3% and a 50.2% success rate. Petusky covers the Healthcare sector, focusing on stocks such as Merit Medical Systems, ATI Physical Therapy, and US Physical Therapy.
Currently, the analyst consensus on Tivity Health is a Hold with an average price target of $28.33.
AbbVie (ABBV)
BMO Capital analyst Gary Nachman maintained a Buy rating on AbbVie today and set a price target of $134.00. The company’s shares closed last Tuesday at $127.29, close to its 52-week high of $127.85.
According to TipRanks.com, Nachman ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -5.0% and a 39.8% success rate. Nachman covers the Healthcare sector, focusing on stocks such as Bausch Health Companies, Pacira Pharmaceuticals, and Aquestive Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for AbbVie with a $134.67 average price target, a 7.1% upside from current levels. In a report issued on December 6, J.P. Morgan also maintained a Buy rating on the stock with a $140.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on GILD: